Longitude Capital: Venture Growth Investing in Healthcare
Longitude Capital: Venture Growth Investing in Healthcare
Description: Quanta Therapeutics is pioneering allosteric modulation to directly restore conformational control of active RAS signaling at the cell membrane to inhibit the full scope of RAS-driven cancer types.
Developing best-in-class allosteric inhibitors for RAS-driven cancers
We are developing allosteric small molecules to target previously undruggable RAS mutations in difficult to treat cancers, including lung, colon and pancreatic cancer. KRAS inhibitors have been developed to target the KRAS G12C mutation, but these therapies are limited to only around ten percent of KRAS-driven cancers and are currently only approved for non-small cell lung cancer patients in later lines of therapy.
We are focused on modulation of RAS signaling at the cell membrane to broaden the scope of treatable RAS-driven cancers. We are applying deep biologic insight, unique protein conformation detection technology and sophisticated medicinal chemistry expertise to develop best-in-class oral small molecules with the potential to lead this next wave of innovation in KRAS therapy.
Longitude Capital: Venture Growth Investing in Healthcare
Longitude Capital: Venture Growth Investing in Healthcare